Bile Acid Synthesis and Absorption in Humans and Rodents {#S1}
========================================================

Bile acid, the end product of cholesterol catabolism, is synthesized in the liver through multiple oxidation and hydroxylation mechanisms ([@B13]; [@B11]). In humans, the bile acids synthesized in the liver are referred to as primary bile acid, including cholic acid (CA) and chenodeoxycholic acid (CDCA) ([@B11]). The secondary bile acids are the transformed form of primary bile acid carried out by gut bacteria through a variety of reactions such as dihydroxylation, dehydrogenation, and epimerization ([@B11]). The secondary bile acids include deoxycholic acid (DCA), ursocholic acid (UCA), ursodeoxycholic acid (UDCA), and lithocholic acid (LCA) ([@B11]).

Bile salts (i.e., conjugated bile acids) exist in different polarities that leads to having at least three different physiological routes of intestinal absorption including: (1) the jejunal passive route, (2) the ileal active and passive transport, and (3) the colonic passive route ([@B35]). Several studies have indicated that the major route of absorption for most conjugated bile acids is the ileal active transport route, while the passive absorption present throughout the small intestine is the main route for unconjugated and some glycine-conjugated bile acids ([@B11]). The design of bile acid transport is so efficient that only 5% of bile acid in the lumen is excreted in feces and the other 95% returns to the liver through the enterohepatic system ([@B36]; [@B11]). Intuitively, these processes make sense as bile acids become more hydrophobic through deconjugation process by gut bacteria allowing for passive transport. In this regard, there is also decreased expression of the apical sodium dependent bile acid transporter (ASBT) in the colon ([@B35]; [@B25]).

There are various studies indicating that ASBT is the major transporter responsible for efficient uptake of bile acid in the terminal ileum ([@B11]). The location of this transporter has been shown in diagrammatic form in previous publications (e.g., [@B27]).

The inactivation of ASBT gene in mice caused a reduction in the enterohepatic circulation of bile acids ([@B10]; [@B29]; [@B57]). Also, there is evidence showing intestinal bile acid malabsorption (BAM) in humans with an ASBT loss-of-function mutation ([@B40]). Of pertinence to this review, the first report of a dysfunctional ASABT mutation was found in the ileum of a Crohn's Disease (CD) patient ([@B61]; [@B33]). Additionally, reduced bile acid absorption occurs in animal models after administration of small molecule inhibitors of the ASBT ([@B26]; [@B62]).

There is an assumption that there must be a cytosolic protein aiding with bile acid transport across the enterocyte just as bile acid is bound to other cytosolic proteins including albumin in plasma ([@B46]; [@B8]; [@B31]). It has been found that this protein is the ileal bile acid-binding protein (IBABP), which is an abundant cytosolic protein ([@B47]). Finally, the transported bile acid exits the enterocyte via organic solute transporter (OSTα/β transporter), functioning in a sodium-independent manner, and predominantly enters the portal venous system ([@B13]; [@B36]).

In a pre-clinical model, Farnesoid X Receptor (FXR) activation causes reduced bile acid uptake by downregulation of ASBT expression in enterocytes. Moreover, FXR activation promotes the excretion of bile acids on the basolateral side of the enterocyte by increasing OSTα and OSTβ expression, which affects the transport of bile acids into the circulation ([@B52]).

It should also be noted that there are differences in bile acid metabolism between humans and rodents (mice, rats). For example, in rodents bile acids are hydroxylated at the 6-beta position to form muricholoic acids (MCAs), which is a group of bile acids unique to these species ([@B45]).

Bile acid absorption in the terminal ileum (and colon) is a critical component for their enterohepatic circulation. This process can be altered during Inflammatory Bowel Disease (IBD). In this regard, diarrhea in patients with IBD may be partially dependent on bile acid malabsorption ([@B27]).

Pre-clinical Observations {#S2}
=========================

Pertinent information is presented below from rodent, rabbit, canine and non-human primate models, as related to this overall topic. Moreover, pre-clinical observations related to bile acid transport proteins (e.g., ASBT) and fecal bile acids in animal models of IBD/intestinal inflammation are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Bile acid transport proteins and fecal bile acids in animal models of IBD/Intestinal inflammation.

  IBD model/species                      Reference number   Effect(s) on BA transporters                                                                Effect(s) on bile acids or lipids
  -------------------------------------- ------------------ ------------------------------------------------------------------------------------------- --------------------------------------------------------------
  TNBS/Rat                               21                 Decreased ASBT expression (60% during acute phase).                                         Total bile acid levels in the feces were increased 1.6 fold.
  TNBS/Hamster                           25                 Not measured                                                                                Decreased bile acid uptake in the ileum
  TNF^ΔARE/WT^/ Mouse                    26                 Decreased ASBT expression (22%). Also decreased expression of Ostα and Ostβ transporters.   Not measured
  IL-10 deficient Mouse                  28                 Increased ASBT expression                                                                   Decreased total fecal bile acids
  DSS/Mouse                              31                 Not measured                                                                                Increased fecal lipids in mice with colitis.
  DSS/Rat                                35                 Not measured                                                                                Increased fecal cholic acid
  Chronic Inflammatory Enteropathy/Dog   36                 Decreased ASBT expression                                                                   Increased fecal primary bile acids
  Chronic Enteropathy/Dog                38                 Not measured                                                                                Decreased fecal secondary bile acids
  Indomethacin/Mouse                     41                 Decreased ASBT, decreased Ostα and Ostβ                                                     Increased fecal bile acid excretion (32%)
  Indomethacin/Rat                       42                 Decreased mRNA and protein levels of ASBT                                                   Not measured
  Ileitis/Rabbit                         41,43              Decreased mRNA and protein levels of ASBT                                                   Decreased uptake of bile acid

The intracolonic administration of Trinitrobenzene Sulfonic Acid (TNBS) to rodents (rats, mice) is a commonly used model of CD ([@B51]; [@B17]; [@B24]; [@B16]). Using this model, investigators showed decreased expression of intestinal ASBT primarily during the acute phase of the colitis ([@B24]). Of note, in conjunction with the decreased expression of ASBT, there was increased fecal excretion of bile acids, as well as diarrhea in rats with acute TNBS-induced colitis ([@B27]). The diarrhea was likely due to the excess bile acids in the colon, which would stimulate increased secretion of electrolytes/water, as well as increased motility ([@B24]). Interestingly, in conjunction with this study, intestinal FGR expression was not affected, but expression of a target gene \[small heterodimer partner (SHP)\] was significantly reduced ([@B27]). Using a variation of the standard model, investigators showed that instillation of TNBS into the ileum of hamsters resulted in ileitis. In animals with ileitis, active bile acid uptake (i.e., taurocholate) decreased by 84% in the terminal ileum and by 58% in the proximal ileum ([@B48]).

The TNF^ΔARE/WT^ murine model of ileitis is a model of CD that is dependent on the pro-inflammatory cytokine TNF-α ([@B30]; [@B55]). With this model, investigators recently showed decreased expression of ASBT, as well as the basolateral enterocyte efflux transporters, Organic Solute Transporters alpha and beta (Ostα and Ostβ) in mice with ileitis ([@B55]). Interestingly, administration of tauroursodeoxycholic acid (TUDCA) (in the drinking water) to mice partially reversed the attenuated expression of these transport proteins. Moreover, TUDCA partially improved histopathological and "clinical" parameters of murine ileitis ([@B55]). The investigators emphasized that this ileitis model was a more appropriate animal model of IBD to study alterations in bile acid transporters, because \>95% of the intestinal bile acid pool does not transit to the colon due to typically efficient reabsorption in the distal ileum ([@B55]).

IL-10 deficient mice develop a chronic inflammation in the intestinal tract, including the colon and ileum ([@B32]; [@B43]). Using this CD model, intriguing results were reported by Rau and colleagues ([@B43]). They found increased ileal ASBT expression in mice with colitis (albeit at the mRNA level). This seemed to coincide with a decreased total fecal bile acid content in mice with colitis. Is it possible that due to the chronic nature of the intestinal inflammation (i.e., mice were euthanized at 6--12 months of age) that there was compensatory rebound effect involving the ASBT bile acid transporter, and consequently ileal uptake of bile acids?

Dextran Sulfate Sodium (DSS) administered in the drinking water is a common way of inducing colitis in mice ([@B18]; [@B5]). Using this model of Ulcerative Colitis (UC), Bitzer et al. demonstrated a significant increase in total fecal lipids within the colons of mice with colitis. These results indicate overall lipid malabsorption in conjunction with this colitis model. Unfortunately, intestinal bile acid levels were not measured with this study ([@B5]).

DCA is hydrophobic. Therefore, it can cause cytotoxicity to cells. Some investigators have shown that higher fecal bile acid hydrophobicity is associated with an exacerbation of DSS-induced colitis in mice ([@B49]). Moreover, Zhao et al. showed that intracolonic administration of DCA worsened murine DSS-induced colitis. This pro-colitis effect was associated with an increased colonic IL-1β content, in conjunction with NLRP3 inflammasome activation. From a potential therapeutic standpoint, treatment with a caspase 1 inhibitor (Belnacasan) improved parameters of colitis ([@B64]).

Recently, the same group of investigators suggested that exacerbation of DSS-induced colitis in mice by DCA involved the sphingosine-1-phosphate 2 receptor (SIPR2). Treatment with a S1PR2 antagonist improved this colitis. Therefore, targeting the S1PR2 may represent a rationale pharmacological approach for intestinal inflammation, in certain patients still consuming a high fat diet ([@B63]). Araki et al. found significantly increased cholic acid levels in rats with DSS-induced colitis. Interestingly, there was a significant association between the concentration of fecal cholic acid and area of macroscopic injury in the rat colon ([@B2]).

Dogs with chronic inflammatory enteropathy (CIE) have evidence of intestinal inflammation, fecal bile acid dysmetabolism and persistent diarrhea ([@B19]; [@B21]). Giaretta and colleagues found that dogs with CIE had decreased ileal ASBT protein expression. Interestingly, there was a significant negative correlation in this study between the cumulative histopathology score in the ileum and ileal ASBT expression. Moreover, dogs with CIE also had increased primary bile acids (e.g., chenodeoxycholic acid) in the feces compared to the control group of animals, suggesting bile acid dysmetabolism ([@B19]). Moreover, secondary fecal unconjugated bile aids were decreased in dogs with a steroid responsive form of IE. Upon treatment of dogs with prednisone, there was a drug-induced increase in the fecal unconjugated bile content. It was concluded that corticosteroids therapeutically managed canine CIE by affecting bile acid dysmetabolism ([@B21]).

A very recent publication revealed that dogs classified as having Chronic Enteropathy (CE) showed reduced secondary bile acids (lithocholic and deoxycholic acid) in the feces, accompanied by intestinal microbial dysbiosis ([@B58]). Treatment with a hydrolyzed protein diet decreased the abundance of pathogenic bacterial species (e.g., *Escherichia coli* and *Clostridium perfringens*), and concomitantly increased the levels of secondary bile acids. Of note, there was a quick and prolonged clinical response to the diet-based therapy in most dogs with CE. Interestingly, the investigators found that levels of a bile acid producing bacteria (*Clostridium hiranonis*) were increased after dietary therapy and was linked to the clinical remission found in dogs with CE. Finally, when *Clostridium hiranonis* was administered to mice with DSS-induced colitis there was an amelioration of disease activity ([@B58]).

Cotton top tamarins are small "New World Monkeys," which have a propensity to spontaneously develop idiopathic colitis and colonic adenocarcinoma ([@B3]; [@B59]). It is recognized as a unique non-human primate model of UC ([@B59]). Ausman and colleagues conducted a study that monitored fecal bile acids in these animals. They observed lower levels of secondary bile acids (indicating a reduced rate of microbial cholesterol conversion) in cotton top tamarins compared to humans and other animal species ([@B3]).

Indomethacin-induced acute ileitis led to repression of ASBT in wild-type mice. In contrast, activation of ASBT was seen in c-fos--null mice. Counter-intuitively, indomethacin-induced ileal damage was greater in these c-fos--null mice compared with wild-type mice. Indomethacin treatment also led to repression of both Ostα and Ostβ mRNAs. Fecal bile acid excretion was also increased by 32% in mice treated with indomethacin. Mechanistically, the investigators concluded that mouse ASBT is inhibited by inflammatory cytokines via direct interactions of c-fos with the ASBT promoter ([@B38]). In turn, this impacts fecal bile acid levels in mice. They also showed that Indomethacin-induced ileitis in Lewis rats resulted in specific reductions in ileal ASBT messenger RNA and protein levels, whereas c-jun and c-fos proteins were induced in the study. The authors suggested that such "inflammation is associated with up-regulation, phosphorylation, and nuclear translocation of c-fos, which then represses ASBT promoter activity via binding of the 3' AP-1 element by a c-fos/c-jun heterodimer" ([@B9]).

A rabbit model of ileitis was also reported to be associated with the downregulation of ASBT, at both the messenger RNA and protein levels ([@B50]; [@B38]). Moreover, designed kinetic studies demonstrated that sodium-bile acid cotransport was inhibited by a decrease in both the affinity and maximal rate of uptake, of bile acids ([@B50]).

Finally, using a murine colitis associated cancer (CAC) model; investigators showed decreased intestinal mRNA levels of ASBT. Additionally, primary bile acids and taurine-conjugates were increased in the feces of CAC mice ([@B7]). Of note, ileal FXR expression was significantly reduced in CAC mice, and proposed to play a prominent role in the carcinogenesis process ([@B7]).

It should be emphasized that a common mechanism involved in these preclinical models of IBD/intestinal inflammation is decreased ASBT expression ([@B50]; [@B9]; [@B38]; [@B55]; [@B19]; [@B24]). This information is summarized within [Table 1](#T1){ref-type="table"}.

Clinical Observations {#S3}
=====================

In order to confirm the bile acid malabsorption in Crohn's disease (CD) patients, Nishida and colleagues administered chenodeoxycholic-11, 12-d~2~ acid to eight patients and compared them with four volunteer control patients ([@B39]). The results of this study demonstrated "significant reductions of the biological half-life of chenodeoxycholic-11, 12-d2 acid, the pool size of chenodeoxycholic acid, and the total bile acid pool size in patients with Crohn's disease as compared with those in normal subjects" ([@B39]). Thus, they concluded the diminished pool size of bile acid in CD was due to impaired absorption at the ileum ([@B7]). One of the important neglected symptoms of IBD (especially in ileal CD) is BAM ([@B56]). One of the main reasons for BAM in patients with CD is the impaired distal ileum where most of the conjugated and unconjugated bile acids are reabsorbed ([@B39]). This statement is also supported by a study in pediatric IBD patients showing BAM in 86% of patients with no or minimal CD clinical activity ([@B20]). In 1967, Hofmann defined this phenomenon as "cholerheic enterohepathy," known as "type 1 or secondary bile acid malabsorption," which can lead to diarrhea caused by reduced BA reabsorption due to ileal pathology ([@B22]; [@B42]). More specifically, BAM in patients with CD involving ileal disease affects colonic fluid and electrolyte secretion leading to diarrhea ([@B56]).

A case-control study (by [@B53]) study suggested various reasons for BAM in CD patients. In this regard, "mRNA expression levels of ASBT, breast cancer-related protein (BCRP), sulfotransferase family 2A member 1 (SULT2A1), and fibroblast growth factor 19 (FGF-19) were significantly lower in inflamed regions in patients with active Crohn's ileitis than in controls" ([@B53]). The reduced level of FGF-19 enhances the hepatic synthesis of bile acid thereby leading to increased intraluminal bile acid concentration and diarrhea in CD patients ([@B53]). However, the malabsorption of bile acid is so significant that the hepatic synthesis does not atone for the bile acid loss leading to increased concentration of bile acid in the feces.

Interestingly, studies have demonstrated a significant reduction of nuclear receptors including pregnane X (PXR) and farnesoid X (FXR) in CD patient ([@B60]). These nuclear receptors regulate pathways that are compromised in patients with IBD. Specifically, bile acids are endogenous ligands for these nuclear receptors. The CD-induced dysregulation of bile acid profiles leads to reduced expression of these receptors, which causes attenuated levels of key target genes (i.e., CYP450 3A4 and FGF-19). Clinically, this would impact optimal dosing of CYP3A4 substrate drugs (e.g., corticosteroids) in patients with CD. Moreover, the reduction in FGF-19 could cause increased bile acid excretion in the feces and IBD-induced diarrhea ([@B53]; [@B60]).

Finally, severe BAM in patients with CD leads to a significant reduction of the intraduodenal bile acid pool, which impairs the micelle formation involved in fat digestion and cholesterol absorption. Further details regarding the BAM-induced alteration of cholesterol metabolism and absorption have been presented previously in the relevant literature ([@B15]; [@B37]; [@B44]; [@B56]). BAM can also lead to many pathophysiological sequelae such as non-alcoholic steatohepatitis (NASH), which are beyond the scope of this review ([@B1]).

Bile Acid Transporters in IBD {#S4}
=============================

A study conducted by Jahnel et al. demonstrated a significant reduction of about 36% in ileal ASBT mRNA expression from CD patients ([@B27]). The ASBT expression was also attenuated in CD patients in remission ([@B27]). Jung et al. observed a significant reduction in ASBT expression in the majority of sixteen CD patients compared with controls ([@B28]) ([Table 2](#T2){ref-type="table"}). Interestingly, this study illustrated the activation of human ASBT gene (SLC10A2) by direct binding of dexamethasone and budesonide to the glucocorticoid receptors in the promoter region ([@B28]). This result implicates an action for glucocorticoids on the human bile acid uptake system, with the possibility of a treatment-related effect on IBD ([@B28]). Thus, one of the therapeutic effects of glucocorticoids in IBD could be partly explained because of an increased expression of ASBT.

###### 

Bile acid transport proteins and bile acid malabsorption in human IBD.

  IBD type                                 Reference number   Effect(s) on BA transporters                                                                                   Effect(s) on bile acids or lipids
  ---------------------------------------- ------------------ -------------------------------------------------------------------------------------------------------------- -----------------------------------------
  Crohn's disease and Ulcerative Colitis   20                 Decreased ASBT expression (36% reduction of ASBT mRNA expression in active CD and UC and in CD in remission)   Decreased uptake of bile acid, diarrhea
  Crohn's disease                          56                 Decreased ASBT expression by 7.5%                                                                              Not measured

Bam Diagnosis {#S5}
=============

One pertinent study demonstrated that the localization of inflammation is not enough to determine the severity of BAM. Therefore, laboratory testing of BAM is needed for all symptomatic patients to identify those candidates for BA sequestrants (e.g., cholestyramine) ([@B34]). "The gold standard diagnosis of BAM is the TauroH-23-(^75^Se) selena-25-homocholic acid 23-seleno-25homo-tauro-cholic acid-test (SeHCAT)" ([@B34]; [@B14]). In this test, the isotope is orally administered and after 7 days the remaining isotope is measured using a gamma camera. BAM is indicated if the retention of radiolabeled bile acid ^75^SeHCAT is less than 10--15% of the administered tracer ([@B34]).

Other studies have utilized the C4 test to diagnose BAM. In this regard, 7α-hydroxy-4-cholesten-3-one (C4) is a bile acid precursor. For instance, Camilleri et al., demonstrated an increased level of 7αC4 in 46% of patients having ileal disease and 55% in patients with ileal resection ([@B6]). This technique may represent a non-invasive diagnostic advantage to potentially diagnose BAM in patients with ileal disease.

BAM Treatment-IBD {#S6}
=================

Type 1 BAM was identified to be secondary to ileal dysfunction, as related to CD in the ileum and/or ileal resection. "The estimated prevalence of BAM is \>90% in patients with resected CD and 11--52% for non-resected CD patients" ([@B4]). Studies have shown that approximately 83% of chronic diarrhea in patients with BAM has resolved with short-course cholestyramine therapy. "Other bile acid sequestering agents, such as colestipol and colesevelam, are currently being investigated for the treatment of BAM-associated diarrhea" ([@B4]).

Using a post hoc analysis comparing colesevelam alone, cholestyramine alone, loperamide alone, and colesevelam with loperamide; the results suggested colesevelam was an effective treatment for post-operative BAM in CD compared to other options ([@B12]; [@B54]). Hofmann and Poley found that CD patients with \<1 m intestinal resections responded well to bile acid sequestrants, while those with \>1 m resections did not respond ([@B23]). Glucocorticoids may improve BAM in patients with active ileal inflammation by remission induction ([@B28]; [@B41]).

Summary {#S7}
=======

Many pre-clinical studies have shown BAM in animal models of intestinal inflammation/IBD. Decreased ASBT expression was noted in many of these studies, providing a mechanistic basis for the BAM. BAM related studies in patients with ileal Crohn's Disease have demonstrated a reduced pool of bile acids, as the ileum is the main site of conjugated and unconjugated bile acid reabsorption. Type 1 BAM is a neglected and underdiagnosed symptom of CD, which has led to many cases of diarrhea due to bile acid spillover into the colon. Like the pre-clinical data, relevant studies have also demonstrated significant reductions of expression for ASBT.

In one clinical study, most patients with BAM associated diarrhea responded to the short-term use of colesevelam. Some studies have shown the efficacy of glucocorticoids in inducing remission and as a potential treatment for CD. Positive steroid treatment results have occurred in a canine model of intestinal inflammation. Future joint studies, which utilize learnings from both pre-clinical and clinical studies, may help to further delineate optimal treatments for BAM-associated diarrhea in patients with CD.
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